Daratumumab for delayed RBC engraftment following major ABO mismatched haploidentical bone marrow transplantation.

Bonnie YatesEoghan MolloyAlina Dulau-FloreaRaul BraylanLaura HoganDennis D HicksteinAlexandra F FreemanShelley S KalsiNirali N Shah

Published in: Transfusion (2021)

Our experience suggests that daratumumab was an effective first-line therapy for delayed RBC engraftment and that earlier consideration for daratumumab in treatment of delayed RBC engraftment may be warranted.

Keyphrases

bone marrow
multiple myeloma
red blood cell
hematopoietic stem cell
mesenchymal stem cells
peripheral blood